This week, physicists at CERN reported the transmutation of lead into gold in the Large Hadron Collider, raising the ...

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

The authors present an important set of data implicating ETFDH as an epigenetically suppressed gene in cancer with tumor suppressive functions. The evidence is solid, with the authors demonstrating ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

Senti Biosciences, Inc.’s SNTI share price has dipped by 6.26%, which has investors questioning if this is right time to buy.

Alexis McCarthy, a freshman at South Glens Falls High, is recovering from a successful surgery to remove a rare childhood ...

The risk of dying from the most common form of primary liver cancer is approximately 30% higher for patients with low ...

Industry Giants Gilead Sciences, Bristol Myers Squibb, AbbVie, and Merck & Co. Lead the CompetitionDublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Liver Disease Treatments Market" report has been added ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according ...

Among patients with hepatocellular carcinoma, MAFLD was not an independent predictor for overall survival or progression-free survival.